Literature DB >> 12145691

A novel MPL point mutation resulting in thrombopoietin-independent activation.

M Abe1, K Suzuki, O Inagaki, S Sassa, H Shikama.   

Abstract

Thrombopoietin (TPO) and its receptor (MPL) are important regulators of megakaryopoiesis. MPL belongs to a cytokine receptor superfamily. To date, all constitutively active MPL mutants have been artificially constructed with amino acid substitutions in the transmembrane domain or extracellular domain of the protein, and they activate signal transduction pathways in Ba/F3 cells that can also be activated by the normal MPL. In this paper, we report a novel spontaneously occurring mutation of MPL, with an amino acid substitution of Trp(508) to Ser(508) in the intracellular domain of MPL, that induces the factor-independent growth of Ba/F3 cells. Examination of intracellular signaling pathways demonstrated that the mutant MPL protein constitutively activates three distinct signaling pathways, SHC-Ras-Raf-MAPK/JNK, JAK-STAT, and PI3K-Akt-Bad.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145691     DOI: 10.1038/sj.leu.2402554

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Inhibition of GSK-3beta promotes survival and proliferation of megakaryocytic cells through a beta-catenin-independent pathway.

Authors:  Mie Soda; Karl Willert; Kenneth Kaushansky; Amy E Geddis
Journal:  Cell Signal       Date:  2008-09-06       Impact factor: 4.315

2.  Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.

Authors:  J-P Defour; I Chachoua; C Pecquet; S N Constantinescu
Journal:  Leukemia       Date:  2015-10-06       Impact factor: 11.528

Review 3.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

4.  An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.

Authors:  Judith Staerk; Catherine Lacout; Takeshi Sato; Steven O Smith; William Vainchenker; Stefan N Constantinescu
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

5.  An ENU-induced recessive mutation in Mpl leads to thrombocytopenia with overdominance.

Authors:  E Ricky Chan; Heather Lavender; Geqiang Li; Peter Haviernik; Kevin D Bunting; Mark D Adams
Journal:  Exp Hematol       Date:  2008-12-06       Impact factor: 3.084

6.  Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation.

Authors:  Jean-Philippe Defour; Miki Itaya; Vitalina Gryshkova; Ian C Brett; Christian Pecquet; Takeshi Sato; Steven O Smith; Stefan N Constantinescu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

7.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

Review 8.  Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.

Authors:  Isabelle Plo; Christine Bellanné-Chantelot; Matthieu Mosca; Stefania Mazzi; Caroline Marty; William Vainchenker
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-12       Impact factor: 5.555

9.  Prognostic significance of mutated genes in megakaryocytic disorders.

Authors:  Ali Amin Asnafi; Mohammad Bagher Mohammadi; Hadi Rezaeeyan; Nader Davari; Najmaldin Saki
Journal:  Oncol Rev       Date:  2019-07-22

10.  Two activating mutations of MPL in triple-negative myeloproliferative neoplasms.

Authors:  Juan Xie; Xiuhua Chen; Feng Gao; Ruixia Hou; Tingting Tian; Yaofang Zhang; Lifang Fan; Jinjun Hu; Guiyang Zhu; Wanfang Yang; Hongwei Wang
Journal:  Cancer Med       Date:  2019-07-11       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.